Real-world outcomes among US Merkel cell carcinoma patients initiating immune checkpoint inhibitors or chemotherapy

Autor: Sunandana Chandra, Ruth Kim, Ting Yu, Ying Zheng, Mairead Kearney, Hemant Phatak, Li Wang, Shivani Pandya
Rok vydání: 2020
Předmět:
0301 basic medicine
Oncology
Male
Cancer Research
medicine.medical_specialty
Skin Neoplasms
Immune checkpoint inhibitors
medicine.medical_treatment
Antineoplastic Agents
Time to next treatment
Comorbidity
Kaplan-Meier Estimate
03 medical and health sciences
0302 clinical medicine
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Medicine
Humans
Immune Checkpoint Inhibitors
Retrospective Studies
Chemotherapy
Duration of Therapy
business.industry
Merkel cell carcinoma
Real world outcomes
food and beverages
General Medicine
Health Care Costs
Veterans health
medicine.disease
Prognosis
Combined Modality Therapy
United States
nervous system diseases
Carcinoma
Merkel Cell
030104 developmental biology
Treatment Outcome
030220 oncology & carcinogenesis
Per patient per month
Female
business
Zdroj: Future oncology (London, England). 16(31)
ISSN: 1744-8301
Popis: Aim: Retrospectively assessed treatment patterns and clinical and economic outcomes in Merkel cell carcinoma (MCC) patients receiving recommended first-line regimens. Materials & methods: MCC patients newly treated with either immune checkpoint inhibitors (ICIs) or chemotherapies (CTs) were selected from the Veterans Health Administration database (2013–2018); 74 patients (ICIs: 20 and CTs: 54) were selected. Results: Median duration of therapy was 300 days for ICIs and 91 days for CTs. Time to next treatment was 245 and 184 days, respectively. Mean total (per patient per month) costs were $15,306 (ICIs) and $10,957 (CTs), of which 51% and 86%, respectively, were non-MCC therapy-related costs. Conclusion: Despite higher costs, utilization of ICIs in first-line MCC shows clinical advantages over CTs in the real world.
Databáze: OpenAIRE
Externí odkaz: